Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions

Abstract

Prostate cancer (PCa) is one of the most common malignancies and one major leading cause of cancer mortality in elder men. Due to its specific overexpression in PCa cells, the prostate-specific membrane antigen (PSMA) has become an ideal molecular imaging target for PCa. Currently, the value of PSMA PET/CT in the diagnosis and staging of PCa has been widely accepted. With the clinical application of simultaneous PET/MRI, it enables the possibility of combination of PSMA PET and MRI for the management of PCa. Here we present this review on the current status and future direction of the application of PSMA PET/MRI in the management of PCa.